With FDA nod, AstraZeneca's FluMist becomes first self-administered flu vaccine
AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on AstraZeneca's influenza vaccine FluMist for self-administration by adults up to 49 years old and for administration by a parent or caregiver in kids between the ages of 2 and 17.
AstraZeneca PLC AZN shares inched down 0.99% to £117.80 Friday, on what proved to be an all-around rough trading session for ...
In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...
AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...
AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...
AstraZeneca PLC AZN shares inched down 0.40% to £119.68 Tuesday, on what proved to be an all-around great trading session for ...
AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on ...
If the trial design doesn't cause regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated ...
London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...
AstraZeneca Pharma India to launch Palivizumab in India, a drug to prevent RSV in high-risk children. Stocks rise.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback